Effect of glucose variability on pathways associated with glucotoxicity in diabetes: Evaluation of a novel in vitro experimental approach

Diabetes Research and Clinical Practice

Volumn 114, Issue , 2016, Pages 1-8

  Kuricová, Katarína ^a   Pácal, Lukáš ^a   Šoupal, Jan ^b   Prázný, Martin ^b   Kaňková, Kateřina ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Continuous glucose monitoring; Diabetes complications; Glycaemic variability; Hyperglycaemia; Hypoglycaemia; Pentose phosphate pathway

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEME OXYGENASE 1; LACTOYLGLUTATHIONE LYASE; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN P53; TRANSKETOLASE; BIOLOGICAL MARKER; GLUCOSE; GLUCOSE BLOOD LEVEL; MESSENGER RNA;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; GLO1 GENE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOTOXICITY; HMOX1 GENE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RAGE GENE; SOD2 GENE; THTR1 GENE; TKT GENE; UMBILICAL VEIN ENDOTHELIAL CELL; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 1; DNA MICROARRAY; DRUG EFFECTS; EVALUATION STUDY; GENE EXPRESSION PROFILING; GENETICS; HYPOGLYCEMIA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; BIOMARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION PROFILING; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; IN VITRO TECHNIQUES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84958951691     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.02.006     Document Type: Article

References (34)

1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
3. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial, Diabetes. 1995; 44:968-970.
4. Monnier L., Colette C. Glycemic variability: should we and can we prevent it?. Diabetes Care 2008, 31(Suppl 2):S150-S154.
5. Siegelaar S.E., Holleman F., Hoekstra J.B., DeVries J.H. Glucose variability; does it matter?. Endocr Rev 2010, 31:171-182.
6. Hirsch I.B., Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J Diabetes Complications 2005, 19:178-181.
7. Rabbani N., Thornalley P.J. Dicarbonyl proteome and genome damage in metabolic and vascular disease. Biochem Soc Trans 2014, 42:425-432.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
9. Roberts L.J., Morrow J.D. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biol Med 2000, 28:505-513.
10. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
11. Wentholt I.M., Kulik W., Michels R.P., Hoekstra J.B., DeVries J.H. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008, 51:183-190.
12. Monnier L., Colette C., Mas E., et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010, 53:562-571.
13. Siegelaar S.E., Barwari T., Kulik W., Hoekstra J.B., DeVries J.H. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol 2011, 5:86-92.
14. Ceriello A., Esposito K., Piconi L., et al. Glucose peak and glucose spike: Impact on endothelial function and oxidative stress. Diabetes Res Clin Pract 2008, 82:262-267.
15. Ceriello A., Esposito K., Piconi L., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.
16. Maiorino M.I., Della Volpe E., Olita L., Bellastella G., Giugliano D., Esposito K. Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes. Endocrine 2015, 48:342-345.
17. Jones S.C., Saunders H.J., Qi W., Pollock C.A. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia 1999, 42:1113-1119.
18. Takeuchi A., Throckmorton D.C., Brogden A.P., Yoshizawa N., Rasmussen H., Kashgarian M. Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 1995, 268:F13-F19.
19. Del Guerra S., Grupillo M., Masini M., et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 2007, 23:234-238.
20. Risso A., Mercuri F., Quagliaro L., Damante G., Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001, 281:E924-E930.
21. Piconi L., Quagliaro L., Da Ros R., et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004, 2:1453-1459.
22. Piconi L., Quagliaro L., Assaloni R., et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev 2006, 22:198-203.
23. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003, 52:2795-2804.
24. Quagliaro L., Piconi L., Assaloni R., et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005, 183:259-267.
25. Atkins G.B., Jain M.K. Role of Krüppel-like transcription factors in endothelial biology. Circ Res 2007, 100:1686-1695.
26. La Sala L., Pujadas G., De Nigris V., et al. Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress. Acta Diabetol 2015, 52:505-512.
27. Rabbani N., Thornalley P.J. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. Biochem Biophys Res Commun 2015, 458:221-226.
28. Šoupal J., Škrha J., Fajmon M., Horová E., Mráz M., Prázný M. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther 2014, 16:198-203.
29. Zhou J., Li H., Ran X., et al. Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit 2011, 17:CR9-CR13.
30. Negi G., Nakkina V., Kamble P., Sharma S.S. Heme oxygenase-1, a novel target for the treatment of diabetic complications: focus on diabetic peripheral neuropathy. Pharmacol Res 2015, 102:158-167.
31. Brouwers O., Niessen P.M., Ferreira I., et al. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 2011, 286:1374-1380.
32. Gray S.P., Jandeleit-Dahm K. The pathobiology of diabetic vascular complications-cardiovascular and kidney disease. J Mol Med (Berl) 2014, 92:441-452.
33. Bensaad K., Tsuruta A., Selak M.A., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
34. Ceriello A., Ihnat M.A. 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabetes Med 2010, 27:862-867.